FDA UDI Compliance Requirements: What Medical Device Companies Must Know to Stay Ahead

FDA UDI Compliance: A Practical Guide for Medical Device Companies

If you are a medical device startup founder or a regulatory affairs professional at a small-to-mid-sized device company, Unique Device Identification (UDI) compliance is not a checkbox exercise — it is a foundational requirement that affects your labeling, your database submissions, and ultimately your ability to legally market your device in the United States. Yet it remains one of the most frequently misunderstood compliance obligations in the industry.

This post cuts through the noise and gives you exactly what you need to understand the regulatory framework, your specific obligations, and the most common pitfalls that derail companies during FDA inspections and premarket submissions.

The Regulatory Foundation: 21 CFR Part 830

The UDI system is governed by 21 CFR Part 830, which FDA finalized in 2013. The rule established a phased implementation schedule based on device class, and by now, all implantable, life-supporting, and life-sustaining devices — as well as Class III, Class II, and most Class I devices — are required to bear a UDI on their labels and labeling.

The UDI itself consists of two components: the Device Identifier (DI), which is specific to the device version or model, and the Production Identifier (PI), which conveys variable information such as lot number, serial number, manufacturing date, or expiration date. Both must be represented in a plain-text format and in an automatic identification and data capture (AIDC) format — typically a barcode or RFID — unless an exception applies.

GUDID Submission: Your Obligations Under 21 CFR Part 830 Subpart E

Beyond the physical label, manufacturers are required to submit device data to FDA's Global Unique Device Identification Database (GUDID) — the publicly accessible repository that healthcare providers, patients, and regulators use to look up device information. This obligation is codified under 21 CFR Part 830, Subpart E.

Submissions must be made through FDA's AccessGUDID system, and the data must be accurate, complete, and consistent with what appears on your label. The minimum required data elements include:

• The Primary DI number and the issuing agency (FDA accredits three Issuing Agencies: GS1, HIBCC, and ICCBBA)
• Device description and brand name
• MRI safety information where applicable
• Sterilization and latex information
• Whether the device contains a combination product component

One critical point that many companies overlook: GUDID records must be updated whenever a change affects the label or labeling of the device. Failure to maintain accurate GUDID records is a citable observation during FDA facility inspections and can trigger a Form 483.

Labeling Requirements and Common Mistakes

Under 21 CFR 801.20, the UDI must appear on the label of the device, and under 21 CFR 801.45, it must also appear on the device itself for implantable devices, unless doing so is not technically feasible. FDA's guidance document Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices and Certain Devices Requiring Direct Marking (November 2018) provides important clarifications on direct marking expectations.

The most common labeling errors we see at ADB Consulting include:

• Using a DI that has not been properly registered with an FDA-accredited Issuing Agency
• Inconsistencies between the label and the GUDID submission — particularly around device description, size, and version number
• Failing to include the UDI on the package label at each level of packaging, including individual unit, intermediate, and case packaging
• Neglecting to update the DI when a new version or model is introduced
• Incorrectly applying exception criteria under 21 CFR 830.10 to avoid direct marking obligations

UDI in Premarket Submissions: What FDA Expects

UDI compliance is not just an operational concern — it has direct implications for your 510(k), De Novo, and PMA submissions. FDA expects applicants to include the DI for the subject device in their premarket submissions. As noted in FDA's UDI Basics guidance, the DI should be obtained from an accredited Issuing Agency prior to submission, and the associated GUDID record should accurately reflect the device described in the submission.

For companies pursuing a 510(k) clearance, reviewers increasingly scrutinize whether the UDI information aligns with the device description provided in the submission. Discrepancies can result in additional information requests and delays — a costly problem for startups operating on tight timelines.

Practical Steps to Get UDI Right

Here is what a sound UDI compliance program looks like in practice:

• Obtain your DI early — engage with GS1, HIBCC, or ICCBBA well before your planned submission date
• Build GUDID submission into your labeling change control process — treat it as a mandatory workflow step, not an afterthought
• Conduct a UDI labeling audit at each level of packaging before product launch
• Assign ownership — someone in Regulatory Affairs or Quality must own GUDID record maintenance as a defined responsibility
• Review FDA's UDI FAQs and the GUDID Help resources regularly, as submission requirements and system features continue to evolve

The Bottom Line

UDI compliance is deceptively complex. The regulation touches labeling, database management, premarket submissions, and post-market change control simultaneously. Companies that treat it as a one-time task routinely find themselves out of compliance when products are updated or when inspectors look closely at GUDID data integrity.

At ADB Consulting & CRO Inc., we work with medical device startups and established manufacturers to build UDI programs that are accurate, audit-ready, and integrated into their broader Quality Management Systems. Whether you are preparing your first 510(k) or cleaning up a GUDID backlog before an FDA inspection, we can help you get it right — the first time.

Ready to ensure your UDI program is inspection-ready and submission-compliant? Book a free discovery call with Andre Butler and the ADB Consulting team today at adbccro.com. Let's build your compliance program on a foundation that holds up under scrutiny.